Search

Your search keyword '"Clauss-Kobayashi, Julie"' showing total 11 results
Start Over Author "Clauss-Kobayashi, Julie"
11 results on '"Clauss-Kobayashi, Julie"'

3. Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort

Author

Andre, M., Andrieu-Haller, C., Aouizerate, B., Berna, F., Blanc, O., Bourguignon, E., Capdevielle, D., Chereau-Boudet, I., Clauss-Kobayashi, J., Coulon, N., Dassing, R., Dorey, J.M., Dubertret, C., Esselin, A., Fond, G., Gabayet, F., Jarroir, M., Lacelle, D., Leboyer, M., Leignier, S., Llorca, P.M., Mallet, J., Metairie, E., Michel, T., Misdrahi, D., Passerieux, C., Petrucci, J., Pignon, B., Peri, P., Portalier, C., Rey, R., Roman, C., Schorr, B., Schürhoff, F., Szoke, A., Tessier, A., Urbach, M., Wachiche, G., Zinetti-Bertschy, A., Szoke, Andrei, Richard, Jean-Romain, Fond, Guillaume, Misdrahi, David, Lajnef, Mohamed, Aouizerate, Bruno, Boyer, Laurent, Berna, Fabrice, Capdevielle, Delphine, André, Myrtille, Chereau, Isabelle, Clauss-Kobayashi, Julie, Coulon, Nathalie, Dubertret, Caroline, Leignier, Sylvain, Llorca, Pierre Michel, Mallet, Jasmina, Passerieux, Christine, Rey, Romain, Schorr, Benoit, Urbach, Mathieu, Leboyer, Marion, Pignon, Baptiste, and Schürhoff, Franck

Published
2023
Full Text
View/download PDF

4. Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ)

Author

Sunhary De Verville, Pierre-Louis, Stubbs, Brendon, Etchecopar-Etchart, Damien, Godin, Ophélia, Andrieu-Haller, Christelle, Berna, Fabrice, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, Clauss-Kobayashi, Julie, Coulon, Nathalie, Dorey, Jean-Michel, Dubertret, Caroline, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Passerieux, Catherine, Pignon, Baptiste, Rey, Romain, Urbach, Mathieu, Llorca, Pierre-Michel, Schürhoff, Franck, Lançon, Christophe, Boyer, Laurent, and Fond, Guillaume

Published
2022
Full Text
View/download PDF

5. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.

Author

Vidal, Nathan, Roux, Paul, Urbach, Mathieu, Belmonte, Cristobal, Boyer, Laurent, Capdevielle, Delphine, Clauss-Kobayashi, Julie, D’Amato, Thierry, Dassing, Romane, Dubertret, Caroline, Dubreucq, Julien, Fond, Guillaume, Honciuc, Roxana-Mihaela, Leignier, Sylvain, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Pignon, Baptiste, Rey, Romain, and Schürhoff, Franck

Subjects
PARASYMPATHOLYTIC agents, COGNITION disorders, PSYCHIATRIC drugs, LITERATURE reviews, SCHIZOPHRENIA, SCHIZOAFFECTIVE disorders
Abstract

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia. Methods: We identified 27 scales in a literature review. The responses to neuropsychological tests of 839 individuals with schizophrenia or schizoaffective disorder in the FACE-SZ database were collected between 2010 and 2021. We estimated the association between objective global cognitive performance and the 27 scales, the number of psychotropic drugs, and chlorpromazine and lorazepam equivalents in bivariable regressions in a cross-sectional design. We then adjusted the bivariable models with covariates: the predictors significantly associated with cognitive performance in multiple linear regressions were considered to have good concurrent validity to assess cognitive performance. Results: Eight scales, the number of psychotropic drugs, and drug equivalents were significantly associated with cognitive impairment. The number of psychotropic drugs, the most convenient predictor to compute, was associated with worse executive function (Standardized β = -0.12, p = .004) and reasoning (Standardized β = -0.08, p = .037). Conclusion: Anticholinergic burden, the number of psychotropic drugs, and drug equivalents were weakly associated with cognition, thus suggesting that cognitive impairment in schizophrenia and schizoaffective disorder is explained by factors other than medication. The number of psychotropic drugs was the most parsimonious method to assess the risk of iatrogenic cognitive impairment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort

Author

Szoke, Andrei, primary, Richard, Jean-Romain, additional, Fond, Guillaume, additional, Misdrahi, David, additional, Lajnef, Mohamed, additional, Aouizerate, Bruno, additional, Boyer, Laurent, additional, Berna, Fabrice, additional, Capdevielle, Delphine, additional, André, Myrtille, additional, Chereau, Isabelle, additional, Clauss-Kobayashi, Julie, additional, Coulon, Nathalie, additional, Dubertret, Caroline, additional, Leignier, Sylvain, additional, Llorca, Pierre Michel, additional, Mallet, Jasmina, additional, Passerieux, Christine, additional, Rey, Romain, additional, Schorr, Benoit, additional, Urbach, Mathieu, additional, Leboyer, Marion, additional, Pignon, Baptiste, additional, Schürhoff, Franck, additional, Andre, M., additional, Andrieu-Haller, C., additional, Aouizerate, B., additional, Berna, F., additional, Blanc, O., additional, Bourguignon, E., additional, Capdevielle, D., additional, Chereau-Boudet, I., additional, Clauss-Kobayashi, J., additional, Coulon, N., additional, Dassing, R., additional, Dorey, J.M., additional, Dubertret, C., additional, Esselin, A., additional, Fond, G., additional, Gabayet, F., additional, Jarroir, M., additional, Lacelle, D., additional, Leboyer, M., additional, Leignier, S., additional, Llorca, P.M., additional, Mallet, J., additional, Metairie, E., additional, Michel, T., additional, Misdrahi, D., additional, Passerieux, C., additional, Petrucci, J., additional, Pignon, B., additional, Peri, P., additional, Portalier, C., additional, Rey, R., additional, Roman, C., additional, Schorr, B., additional, Schürhoff, F., additional, Szoke, A., additional, Tessier, A., additional, Urbach, M., additional, Wachiche, G., additional, and Zinetti-Bertschy, A., additional

Published
2023
Full Text
View/download PDF

7. Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study

Author

Dubreucq, Julien, Gabayet, Franck, Godin, Ophélia, Andre, Myrtille, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, Clauss-Kobayashi, Julie, Coulon, Nathalie, D’amato, Thierry, Dorey, Jean-Michel, Dubertret, Caroline, Faraldo, Mégane, Laouamri, Hakim, Leigner, Sylvain, Lancon, Christophe, Leboyer, Marion, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Pignon, Baptiste, Schorr, Benoit, Urbach, Mathieu, Schürhoff, Franck, Szoke, Andrei, Berna, Fabrice, Haffen, E, Barteau, V, Bensalem, S, Souryis, K, Petrucci, J, Wahiche, G, Bourguignon, E, Deloge, A, Vilà, E, Blanc, O, Denizot, H, Honciuc, R, Lacelle, D, Pires, S, Portalier, C, Leignier, S, Roman, C, Chesnoy-Servanin, G, Vehier, A, Faget, C, Metairie, E, Peri, P, Vaillant, F, Boyer, L, Fond, Guillaume, Vidailhet, P, Zinetti-Bertschy, A, Michel, T, Garbisson, A, Belmonte, C, Dubois, T, Esselin, S, Jarroir, M, Fondation FondaMental [Créteil], Centre Hospitalier Alpes Isère, IMRB - 'Biologie du système neuromusculaire' [Créteil] (U955 Inserm - UPEC), École nationale vétérinaire - Alfort (ENVA)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Charles Perrens, Nutrition et Neurobiologie intégrée (NutriNeuro), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Clermont Auvergne (UCA), Les Hôpitaux Universitaires de Strasbourg (HUS), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier le Vinatier [Bron], Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Pôle de psychiatrie et d'addictologie des Hôpitaux Universitaires Henri-Mondor [Créteil], Centre hospitalier universitaire Henri-Mondor [Créteil], Centre Hospitalier de Versailles André Mignot (CHV), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg-Université de Strasbourg (UNISTRA), Centre de recherche en neurosciences de Lyon (CRNL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre hospitalier Charles Perrens [Bordeaux], Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)

Subjects
Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Meaningful life, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, Full recovery, personal recovery, Medicine, Humans, psychosocial treatment, 030212 general & internal medicine, full recovery, Depression (differential diagnoses), Analysis of Variance, Chi-Square Distribution, business.industry, Perspective (graphical), Recovery of Function, Mental illness, medicine.disease, clinical recovery, 030227 psychiatry, schizophrenia, Psychiatry and Mental health, Schizophrenia, Quality of Life, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], business, Psychosocial, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Regular Articles
Abstract

Recovery is a multidimensional construct that can be defined either from a clinical perspective or from a consumer-focused one, as a self-broadening process aimed at living a meaningful life beyond mental illness. We aimed to longitudinally examine the overlap and mutual distinctions between clinical and personal recovery. Of 1239 people with schizophrenia consecutively recruited from the FondaMental Advanced Centers of Expertise for SZ network, the 507 present at one-year did not differ from those lost to follow-up. Clinical recovery was defined as the combination of clinical remission and functional remission. Personal recovery was defined as being in the rebuilding or in the growth stage of the Stages of Recovery Instrument (STORI). Full recovery was defined as the combination of clinical recovery and personal recovery. First, we examined the factors at baseline associated with each aspect of recovery. Then, we conducted multivariable models on the correlates of stable clinical recovery, stable personal recovery, and stable full recovery after one year. At baseline, clinical recovery and personal recovery were characterized by distinct patterns of outcome (i.e. better objective outcomes but no difference in subjective outcomes for clinical recovery, the opposite pattern for personal recovery, and better overall outcomes for full recovery). We found that clinical recovery and personal recovery predicted each other over time (baseline personal recovery for stable clinical recovery at one year; P = .026, OR = 4.94 [1.30–23.0]; baseline clinical recovery for stable personal recovery at one year; P = .016, OR = 3.64 [1.31–11.2]). In short, given the interaction but also the degree of difference between clinical recovery and personal recovery, psychosocial treatment should target, beyond clinical recovery, subjective aspects such as personal recovery and depression to reach full recovery.

Published
2022
Full Text
View/download PDF

8. Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia

Author

Korchia, Théo, primary, Tastevin, Maud, additional, Sunhary de Verville, Pierre-Louis, additional, Joober, Ridha, additional, Andrieu-Haller, Christelle, additional, Faugere, Mélanie, additional, Godin, Ophélia, additional, Etchecopar-Etchart, Damien, additional, Berna, Fabrice, additional, Aouizerate, Bruno, additional, Capdevielle, Delphine, additional, Chereau, Isabelle, additional, Clauss-Kobayashi, Julie, additional, Coulon, Nathalie, additional, Dorey, Jean-Michel, additional, Dubertret, Caroline, additional, Dubreucq, Julien, additional, Mallet, Jasmina, additional, Misdrahi, David, additional, Passerieux, Christine, additional, Rey, Romain, additional, Schürhoff, Frank, additional, Szoke, Andrei, additional, Urbach, Mathieu, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Lançon, Christophe, additional, Richieri, Raphaelle, additional, Boyer, Laurent, additional, and Fond, Guillaume, additional

Published
2022
Full Text
View/download PDF

9. Immune signatures of treatment resistant schizophrenia: a FACE-SZ study

Author

Leboyer, Marion, Godin, Ophélia, Terro, Emilie, Boukouaci, Wahid, Lu, Ching-lieng, Andre, Myrtille, Aouizerate, Bruno, Berna, Fabrice, Barau, Caroline, Capdevielle, Delphine, Clauss-Kobayashi, Julie, Chereau, Isabelle, D'Amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Fond, Guillaume, Laouamri, Hakim, Leignier, Sylvain, Lancon, Christophe, Llorca, Pierre-Michel, Mallet, Jasmina, Le Corvoisier, Philippe, Misdrahi, David, Passerieux, Christine, Rey, Romain, Pignon, Baptiste, Urbach, Mathieu, Szoke, Andrei, Schürhoff, Franck, Tamouza, Ryad, Godin, Ophélia, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), and Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
[SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.IMM]Life Sciences [q-bio]/Immunology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

10. Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study.

Author

Leboyer, Marion, Godin, Ophélia, Terro, Emilie, Boukouaci, Wahid, Ching-lieng Lu, Andre, Myrtille, Aouizerate, Bruno, Berna, Fabrice, Barau, Caroline, Capdevielle, Delphine, Clauss-Kobayashi, Julie, Chereau, Isabelle, D'Amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Fond, Guillaume, Laouamri, Hakim, Leignier, Sylvain, Lancon, Christophe, and Llorca, Pierre-Michel

Subjects
SCHIZOPHRENIA, QUALITY of life, DISEASE relapse, INFLAMMATION, ANTIPSYCHOTIC agents
Abstract

Treatment-resistant schizophrenia (TRS) affects around 30% of patients with schizophrenia (SZ) resulting in poor functioning, relapses, and reduced quality of life. Convergent findings show that inflammation could contribute to resistance. We thus search for immune signatures of patients with TRS/ultra TRS (UTRS) in a sample of community-dwelling outpatients with SZ. In total, 195 stabilized SZ patients (mean age = 31.2 years, 73% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia in France and received a thorough clinical assessment. At inclusion, psychotic symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Circulating serum/plasma levels of a large panel of markers reflecting the main inflammatory pathways were evaluated. TRS was defined by current treatment by clozapine (CLZ) and UTRS by current CLZ treatment + PANSS total score ≥ 70. The frequency of TRS and UTRS patients was, respectively, 20% and 7.7% and was defined using multivariable analysis elevated by high levels of interleukin (IL)-12/IL-23p40, IL-17A, IL-10, and beta 2 microglobulin (B2M) and IL-12/ IL-23p40, IL-17A, IL-6, IL-10, IFNγ, and B2M, respectively. These observations suggest that resistance and ultra resistance to CLZ treatment are underpinned by pro-inflammatory molecules mainly belonging to the T helper 17 pathway, a finding making sense given the interplay between inflammation and antipsychotic treatment responses. If confirmed, our findings may allow us to consider IL-23/ IL-17 pathway as a therapeutic target for patients with resistance to antipsychotics. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study.

Author

Dubreucq J, Gabayet F, Godin O, Andre M, Aouizerate B, Capdevielle D, Chereau I, Clauss-Kobayashi J, Coulon N, D'Amato T, Dorey JM, Dubertret C, Faraldo M, Laouamri H, Leigner S, Lancon C, Leboyer M, Llorca PM, Mallet J, Misdrahi D, Passerieux C, Rey R, Pignon B, Schorr B, Urbach M, Schürhoff F, Szoke A, Fond G, and Berna F

Subjects
Adult, Analysis of Variance, Chi-Square Distribution, Female, Humans, Male, Schizophrenia physiopathology, Quality of Life psychology, Recovery of Function physiology, Schizophrenia therapy
Abstract

Recovery is a multidimensional construct that can be defined either from a clinical perspective or from a consumer-focused one, as a self-broadening process aimed at living a meaningful life beyond mental illness. We aimed to longitudinally examine the overlap and mutual distinctions between clinical and personal recovery. Of 1239 people with schizophrenia consecutively recruited from the FondaMental Advanced Centers of Expertise for SZ network, the 507 present at one-year did not differ from those lost to follow-up. Clinical recovery was defined as the combination of clinical remission and functional remission. Personal recovery was defined as being in the rebuilding or in the growth stage of the Stages of Recovery Instrument (STORI). Full recovery was defined as the combination of clinical recovery and personal recovery. First, we examined the factors at baseline associated with each aspect of recovery. Then, we conducted multivariable models on the correlates of stable clinical recovery, stable personal recovery, and stable full recovery after one year. At baseline, clinical recovery and personal recovery were characterized by distinct patterns of outcome (i.e. better objective outcomes but no difference in subjective outcomes for clinical recovery, the opposite pattern for personal recovery, and better overall outcomes for full recovery). We found that clinical recovery and personal recovery predicted each other over time (baseline personal recovery for stable clinical recovery at one year; P = .026, OR = 4.94 [1.30-23.0]; baseline clinical recovery for stable personal recovery at one year; P = .016, OR = 3.64 [1.31-11.2]). In short, given the interaction but also the degree of difference between clinical recovery and personal recovery, psychosocial treatment should target, beyond clinical recovery, subjective aspects such as personal recovery and depression to reach full recovery., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results